Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase 3 INSTRIDE 2 study | diabetes.medicinematters.com

Medicine Matters Diabetes

JAVASCRIPT NEEDED

Please enable JavaScript on your browser, so that you can use all features of this website.

window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'track', 'eventCategory': 'flash_warning', 'eventAction': 'Javascript needed', 'eventLabel': 'Please enable JavaScript on your browser, so that you can use all features of this website.' });

Top

08-15-2018 | Insulin glargine | Article

Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase 3 INSTRIDE 2 study

Blevins TC et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13495

Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.

https://doi.org/10.1111/dom.13495

Version: 0.2061.0

Medicine Matters Diabetes

Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase 3 INSTRIDE 2 study

New additions to the Adis Journal Club

ADA 2022 coverage